In this Issue:
Number of donor alloreactive NK cells correlates with response in elderly AML patients
Gemtuzumab ozogamicin reduces relapse risk in FLT3/ITD AML
Prognostic value of Ki-67, cytology, and growth pattern in mantle cell lymphoma
ABVD vs BEACOPP vs COPP-EBVCAD in Hodgkin lymphoma: 10year results
Interim PET response–adapted therapy in Hodgkin lymphoma
Blinatumomab for relapsed/ refractory NHL
Allogeneic vs autologous transplant in early relapsed/ refractory follicular lymphoma
Short duration immunochemotherapy followed by radioimmunotherapy in relapsed follicular lymphoma
Bendamustine + rituximab and maintenance lenalidomide in relapsed/refractory CLL and SLL
Leukaemia-initiating cells inform outcomes in AML
Please login below to download this issue (PDF)